Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913900 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00913900 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 10 participants.
The verdict
NCT00913900, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Peripheral artery disease (PAD) due to leg artery blockages can result in painful leg muscles, skin ulcers and infection due to poor blood flow. In severe forms, the only treatment may be amputation. Adult stem cells injected into affected legs may cause new blood vessel formation and improve blood flow. The purpose of this study is to determine the feasibility and safety of injecting adult stem cells into the leg muscles of patients with severe PAD, in an attempt to improve blood flow.
Interventions
- BIOLOGICAL autologous CD133+ cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00913900
The ClinicalTrials.gov registry entry for NCT00913900 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous CD133+ cells is the first listed.
NCT00913900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00913900 about?
NCT00913900 is a clinical study titled "Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease". Peripheral artery disease (PAD) due to leg artery blockages can result in painful leg muscles, skin ulcers and infection due to poor blood flow. In severe forms, the only treatment may be amputation. Adult stem cells injected into affected legs may cause new blood vessel formation and improve blood ...
What is the current status of trial NCT00913900?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00913900?
The interventions under investigation include: autologous CD133+ cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00913900?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.